Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

INTERVENTIONALInicio: 22 de nov de 2024ID: NCT05552157

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients With Type 2 Diabetes Mellitus: Two Populations With Different Insulin Treatment Options

INTERVENTIONALInicio: 1 de jun de 2006ID: NCT00330473

Activo, no reclutaFase 3ClinicalTrials.gov

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

INTERVENTIONALInicio: 16 de dic de 2021ID: NCT05147220

CompletadoFase 3ClinicalTrials.gov

A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.

INTERVENTIONALInicio: 1 de ene de 2007ID: NCT00409188

CompletadoFase 2ClinicalTrials.gov

An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients

INTERVENTIONALInicio: 1 de nov de 2007ID: NCT00558337

ReclutandoClinicalTrials.gov

Long-term Risk of Recurrent Cervical Artery Dissection After Pregnancy (LONG-RECAP Study)

OBSERVATIONALInicio: 1 de ene de 2023ID: NCT06258109

CompletadoClinicalTrials.gov

Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART).

OBSERVATIONALInicio: 1 de jun de 2012ID: NCT01637233

CompletadoClinicalTrials.gov

A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE)

OBSERVATIONALInicio: 16 de abr de 2012ID: NCT01480063

CompletadoFase 3ClinicalTrials.gov

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

INTERVENTIONALInicio: 23 de ene de 2019ID: NCT03761849

ReclutandoClinicalTrials.gov

Frequency of Selected Single Nucleotide Polymorphisms in Phase With the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers

OBSERVATIONALInicio: 2 de sept de 2024ID: NCT06667414

Activo, no reclutaFase 3ClinicalTrials.gov

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

INTERVENTIONALInicio: 18 de oct de 2021ID: NCT05104866

TerminadoClinicalTrials.gov

A Global Prospective observationAl Study of Real-worlD managemEnt of patieNts With atrIal fibrillAtion at High Risk of Stroke (GARDENIA)

OBSERVATIONALInicio: 14 de sept de 2022ID: NCT05421533

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)

INTERVENTIONALInicio: 14 de jul de 2025ID: NCT06976216

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

INTERVENTIONALInicio: 24 de sept de 2020ID: NCT04411641

CompletadoFase 3ClinicalTrials.gov

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study

INTERVENTIONALInicio: 1 de ene de 2007ID: NCT00409175

Activo, no reclutaFase 3ClinicalTrials.gov

An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis

INTERVENTIONALInicio: 16 de abr de 2024ID: NCT06372145

CompletadoFase 3ClinicalTrials.gov

A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

INTERVENTIONALInicio: 1 de ene de 2008ID: NCT00623103

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis

INTERVENTIONALInicio: 7 de ago de 2019ID: NCT03840148

TerminadoFase 2ClinicalTrials.gov

Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

INTERVENTIONALInicio: 29 de sept de 2008ID: NCT00706238

TerminadoFase 3ClinicalTrials.gov

A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.

INTERVENTIONALInicio: 1 de dic de 2009ID: NCT00998764